托法替布,掌跖银屑病,JAK抑制剂,IL-17 拮抗剂," /> 托法替布,掌跖银屑病,JAK抑制剂,IL-17 拮抗剂,"/> tofacitinib, palmoplantar psoriasis, JAK inhibitor, IL-17 inhibitor,"/> <span style="font-size:12px;">托法替布治疗对司库奇尤单抗抵抗的掌跖银屑病一例</span>

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (2): 134-136.doi: 10.12144/zgmfskin202402134

• 病例报告 • 上一篇    下一篇

托法替布治疗对司库奇尤单抗抵抗的掌跖银屑病一例

崔寅玲1,2,郑淳之1,2,于咏梅1,2,刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-02-15 发布日期:2024-01-31

Palmoplantar psoriasis resistant to secukinumab successfully treated with tofacitinib: a case report

CUI Yinling1,2, ZHENG Chunzhi1,2, YU Yongmei1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-02-15 Published:2024-01-31

PDF (PC)

83

摘要： 掌跖银屑病是一种斑块型银屑病少见的亚型，容易漏诊和误诊，传统治疗往往效果不佳，IL－17 拮抗剂作为生物制剂在掌跖银屑病疗效良好，但部分患者存在疗效衰减、剂量依赖及不能耐受的现象。JAK抑制剂通过抑制JAK-STAT通路，影响一系列细胞因子的功能，发挥免疫调节作用。本文报道1例用JAK抑制剂托法替布治疗司库奇尤单抗抵抗的掌跖银屑病，并取得良好的疗效。

关键词: 托法替布')">">托法替布, 掌跖银屑病, JAK抑制剂, IL-17 拮抗剂

Abstract: Palmoplantar psoriasis is a rare phenotype of plaque psoriasis that is easy to miss and misdiagnose, and traditional treatments are often ineffective.IL-17 inhibitors are effective as biologics in palmoplantar psoriasis, but there is attenuation of efficacy, dose dependence, and intolerability in some patients. JAK inhibitors could affect a series of cytokines by inhibiting the JAK-STAT pathway, and play an immunomodulatory role. In this paper, we report a case of palmoplantar psoriasis resistant to secukinumab treated with JAK inhibitor tofacitinib, and achieved good results.

Key words: tofacitinib')">">tofacitinib, palmoplantar psoriasis, JAK inhibitor, IL-17 inhibitor